Saturday, October 31, 2026

Moderna Stock Is 4.97% Down So Far On Tuesday

ViaNews Editorial Team

December 1, 2020

Moderna Stock Is 4.97% Down So Far On Tuesday

Shares of Moderna fell 4.97% to $145.15 at 14:11 EST on Tuesday, after three consecutive sessions in a row of gains. The Nasdaq Stock Market is rising 1.47% to $12,377.60, following yesterday's downward trend, on what up until now seems, an all-around positive trend exchanging session today.

Moderna's last close was $152.74, 22.98% under its 52-week high of $178.50.

News about Moderna today

Moderna mania draws bitcoin comparisons while shorts bleed. According to today's article on Bloomberg Quint, "Moderna Mania Draws Comparisons to Bitcoin While Shorts Bleed."

Moderna's Sales

Moderna's sales growth is 1425.2% for the ongoing quarter and 9666.5% for the next. The company's growth estimates for the present quarter is a negative 48.6% and positive 528.6% for the next.

Moderna's Revenue

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Moderna's Stock Top and Bottom Yearly Value

Moderna's stock is valued at $145.15 at 14:11 EST, way below its 52-week high of $178.50 and way above its 52-week low of $17.68.

Moderna's Moving Average

Moderna's worth is way above its 50-day moving average of $82.84 and way higher than its 200-day moving average of $71.63.

Previous days news about Moderna

Moderna set to file for us, EU clearance for its coronavirus vaccine. According to yesterday's article on ForexLive, "Moderna reaffirms that its vaccine is 94.1% effective in primary analysis - Vaccine was 94.1% effective in analysis of Phase 3 study, after 196 virus cases - Vaccine was 100% effective against strict virus cases in trial Another Monday, another dose of vaccine optimism to hit the market."

Moderna to ask FDA to authorize vaccine. According to yesterday's article on The Wall Street Journal, "Moderna will ask U.S"

According to yesterday's article on Bloomberg Quint, "Moderna Plans to Seek U.S., EU Clearance for Covid Vaccine."

Moderna to file EUA for coronavirus vaccine candidate, which previewed 94.1% efficacy. According to yesterday's article on MarketWatch, "Moderna Inc"

According to yesterday's article on MarketWatch, "Moderna shares soar 11% on filing for emergency-use authorization for vaccine."

Stocks making the biggest moves premarket: Moderna, IHS markit, slack & more. According to yesterday's article on CNBC, "Some of the stocks posting the largest moves before the bell include Moderna, IHS Markit, Slack, and more.."

Stocks making the biggest moves premarket: Moderna, IHS markit, slack & more. According to yesterday's article on CNBC, "Some of the stocks posting the largest moves before the bell include Moderna, IHS Markit, Slack, and more.."

Stocks making the biggest moves midday: Moderna, IHS markit, nikola, Carnival & more. According to yesterday's article on CNBC, "Moderna shares rereport on strong efficacy data."

Stocks making the biggest moves midday: Moderna, IHS markit, nikola, Carnival & more. According to yesterday's article on CNBC, "Moderna shares rereport on strong efficacy data."

According to yesterday's article on Bloomberg Quint, "Moderna Seeks Approval; WHO Spotlights Risks: Virus Update."

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com